This is what I took away from the doctors discussion on the call yesterday. This drug is only in the launch stage. Even doctors that know about it have no experience with prescribing it. They need to also make sure that the entire regimen is given. AS time goes on it can become the drug of choice in certain situations.
The incease in the sales force by 25 sales reps will be key, not only for this product but for the others. Awareness is achieved by more visits to the MD's. There is also a problem in estimating actual usage in the beginning due to stocking and how that is accomplished. In order to understand this whole issue you really need to listen to the call. From my perspective the folks that run this company appear to have a good handle on quickly expanding the roll out. The fact that they upped guidance tells me that the dynamics of the roll out are going well. The whole issue of stocking can lead to lumpy results, but I think we will be OK here.
yes sir.. over 8,000 GI docs visited Orlando back a few months ago for their annual CME meeting and SNTS was there to present two Uceris posters. With the increase in the 25 additional reps, SNTS will be able to further engage and educate the GI docs regarding Uceris.